Position in RVMD
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$1,070,722
New position
Shares Held
11,010
first reported quarter
Ownership
0.005%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in RVMD
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$1,069,750
PutShares
11,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026NINE MASTS CAPITAL Ltd holds $7,147,037 across 35 Biotechnology names. RVMD ranks #2 (15.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APLS |
Apellis Pharmaceuticals, Inc.
|
97,478 | $3,921,539 | |
| 2 | RVMD |
Revolution Medicines, Inc.
This page
|
11,010 | $1,070,722 | |
| 3 | ABVX |
Abivax S.A.
|
7,500 | $835,125 | |
| 4 | GALT |
Galectin Therapeutics Inc
|
19,324 | $53,913 | |
| 5 | BMEA |
Biomea Fusion, Inc.
|
32,472 | $49,682 | |
| 6 | OTLK |
Outlook Therapeutics, Inc.
|
232,546 | $47,904 | |
| 7 | PRQR |
ProQR Therapeutics N.V.
|
29,518 | $47,819 | |
| 8 | LCTX |
Lineage Cell Therapeutics, Inc.
|
29,194 | $46,126 |
All Filings in RVMD
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,070,722 | 11,010 | Shares | Sole | 2026-05-13 | |
| 2026-03-31 | $1,069,750 | 11,000 | Put | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||